Skip to main content
. 2016 Feb 25;7(13):16650–16662. doi: 10.18632/oncotarget.7692

Figure 2. Monocytic targeting of HDACi therapy spares normal bone marrow progenitor cells.

Figure 2

(A) Flow cytometric analysis of viability of cell subpopulations in primary AML samples in response to Tefinostat dosing measured by 7AAD exclusion (n = 8). (B) Dose response effects of Tefinostat and CHR8185 in NBM cells (n = 4) measured by 7AAD exclusion. (C) Tefinostat effects on Colony forming units (CFUs) in NBM CD34+ cells (no significant difference, n = 4) and primary AML blasts (*p < 0.02 MWU, n = 6) following 14 days culture on methocult.